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Model Human β Thalassemic 
Erythrocytes: Effect of Unpaired 
Purified α-Hemoglobin Chains on 
Normal Erythrocytes
Mark D. Scott
Abstract
β thalassemias arise from genetic defects that interfere with the synthesis of 
the β hemoglobin chain and the subsequent production of the normal α2β2 hemo-
globin tetramer. As a consequence of this decreased β-chain synthesis, unpaired 
α-hemoglobin chains are found within the red blood cell (RBC). The unstable 
α-chains are associated with a number of cellular defects, including: membrane-
bound globin; membrane thiol oxidation; altered cytoskeletal proteins; decreased 
cellular and membrane deformability; and increased susceptibility to both endog-
enous and exogenous oxidants. Surprisingly, while significant injury to human 
thalassemic RBC arise from the unpaired α-chains, the underlying intra-RBC 
mechanisms are not easily studied in patient samples or in mouse models. To better 
study the fate of excess α-chains in human RBC, the model β Thalassemic cell was 
developed. Model human β thalassemic RBC is made by entrapping purified human 
α-chains within normal RBC via osmotic lysis and resealing. This human model 
allows for the systematic examination of the mechanisms underlying the α-chain 
mediated damage in the β thalassemic RBC. Studies utilizing the model β thalas-
semic RBC have demonstrated that the α-chains give rise to an iron and glutathione-
dependent, self-amplifying and self-propagating oxidative reaction.
Keywords: β thalassemia, α-hemoglobin chains, iron, red blood cell, erythrocyte, 
oxidation, free radicals, glutathione, deformability
1. Introduction
The thalassemias are a major cause of morbidity and mortality throughout much 
of the world [1–9]. Thalassemias are characterized by the disruption of the synthesis 
of normal adult hemoglobin (HbA; an α2β2 tetramer; Figure 1) consequent to a diverse 
array of genetic mutations/deletions to either the β or α-hemoglobin chain genes 
(Chromosomes 11 and 16, respectively). As a consequence of reduced/absent produc-
tion of β-chains, β thalassemia is characterized by the presence of highly unstable 
monomeric α-chains as these chains cannot self-associate and indeed require a chap-
erone protein to prevent precipitation [10]. In contrast, α thalassemia is characterized 
by the presence of relatively stable tetrameric β chains. Interestingly, as schematically 
shown in Figure 1, unlike most genes, there are four copies of the α-globin genes; 
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this is in contrast to the expected two copies of the β-globin genes. The evolutionary 
duplication of the human α-chain genes may have been favored consequent to the 
inherent instability of monomeric α-chains. Indeed, the instability of the α-chains 
is the key factor underlying the pathophysiology of the β thalassemic red blood cell 
(RBC). Moreover, the pathophysiology of β thalassemia can be further complicated by 
the geographical prevalence, and high frequency, of a number of mutated β hemo-
globin genes (e.g., sickle hemoglobin, hemoglobin E and hemoglobin C). If a mutated 
β-chain is the only functional β-chain present, the resultant disease will be more severe 
than that observed in β thalassemia Intermedia (a single normal β-globin gene). Loss 
of both β-chain genes gives rise to severe β Thalassemia Major which is fatal in the 
absence of transfusion therapy. The α thalassemias are characterized by a broader 
range of disease states due to the presence of 4 α genes. The loss of expression from a 
single gene (α Thalassemia1 Trait) is often asymptomatic and undiagnosed; though 
the individual is a carrier for α Thalassemia and, in high frequency geographic areas 
may be at elevated risk for symptomatic disease transmission to an offspring. Deletion 
of two or three α-genes results in severe disease as a single active α-gene cannot, due 
to the instability of the chain, produce sufficient mature α-chains to form sufficient 
HbA. Loss of all four α-genes is fatal (resulting in Hydrops fetalis) due to the crucial 
role that α-chains play in embryonic and fetal hemoglobin. In contrast to β thalas-
semia, stable mutated α-chains are rare so typically these do not pose a significant 
complication in the pathophysiology of α thalassemia.
In this chapter we will further explore the pathophysiology of the β thalassemic 
RBC. Surprisingly, while significant injury to the thalassemic erythrocyte arises 
from the excess α-chains, the underlying mechanisms by which these chains damage 
and subsequently destroy the thalassemic RBC in the bone marrow and peripheral 
blood have not been clearly delineated. Our lack of understanding of the mecha-
nisms of α-chain mediated damage is due, in part, to three major factors: (1) studies 
of RBC from β thalassemic individuals are difficult to do since these cells, upon 
collection, already exhibit significant injury and represent a survivorship bias since 
up to 80% of erythroid precursors are destroyed within the bone; (2) β thalassemic 
patients are typically transfused to both correct the severe anemia accompanying 
the disease and to prevent endogenous erythropoiesis of defective RBC; and (3) the 
lack of a good experimental model by which the pathophysiology of excess globin 
chains on human RBC can be examined.
While little can be done to change the first two problems, researchers have 
attempted to tackle the third issue using murine models of thalassemia [11–17]. 
Original murine studies examining the knockout of the murine β-chains were not 
Figure 1. 
Molecular basis and clinical diagnosis of the α and β thalassemias [1–9]. β* denotes abnormal β hemoglobin 
gene such as HbS or HbE.
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productive as the murine α-chains behave significantly different from their human 
counterpart. To overcome this problem, human α-chain genes were inserted into the 
mouse genome in place of the murine genes. Again, these studies failed to give rise 
to as severe a phenotype as is seen in the human disease. Subsequent studies utilized 
additional mutations to produce symptomatic disease in the murine context—albeit 
with still substantial differences from the pathophysiology seen in the human β 
thalassemic RBC. Hence, an alternative approach for studying the pathophysiology 
of unpaired α-chains on the human RBC was needed.
2. Model human β thalassemic RBC
To this end, our laboratory developed an in vitro model of the HUMAN β 
thalassemic erythrocyte [18–27]. In this model, purified human α-chains are 
entrapped within normal human RBC (or, if desired, mouse RBC) by osmotic 
lysis and resealing (Figure 2) [18–34]. As previously shown, osmotic lysis and 
resealing results in RBC exhibiting normal hemoglobin concentration and volume 
(Table 1) as well as normal ATP concentration, oxidant sensitivity, morphology and 
Figure 2. 
Generation of model β thalassemic RBC from normal human donor cells via osmotic lysis and resealing 
[18–34]. Osmotically lysed and resealed RBC have normal morphology and metabolism and exhibit normal in 
vivo survival.
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deformability while allowing for the efficient entrapment of exogenous compounds 
[18–34]. Indeed, studies with resealed human RBC demonstrate that this meth-
odology can be used to correct enzyme deficiencies, enhance antioxidant levels, 
and be used in vitro to study malarial growth and maturation. Moreover, murine 
studies demonstrated that osmotically resealed murine RBC exhibited normal in 
vivo survival. To manufacture the model β thalassemic RBC from normal human 
donor cells, purified, heme-containing, α-hemoglobin chains were prepared by 
dissociation of CO-treated HbA in the presence of parahydroxymercuribenzoate, 
followed by ion exchange chromatography, to isolate the purified CO-α-chains as 
previously described [1, 18, 20–22, 35, 36]. Analysis of the purified α-chains by 
mass spectroscopy demonstrated the expected mass values for the α-globin chain. 
The purified α-chains can be stored at −80°C as carbon monoxide stabilized chains 
(CO-α-chains) and then thawed immediately prior to use.
Characteristic β thalassemic RBC Model β thalassemic RBC
Microcytic RBC 
(MCV <80 fl)
+ + (progressive)
K+ Loss + +
Unpaired α-chains 1–3% of total hemoglobin in 
peripheral blood reticulocytes
3–4% of total hemoglobin
Membrane Bound 
Globin
Increased Increased; correlated with α-chain 
autoxidation & heme release.
Membrane proteins/
thiols
Loss of spectrin and ankyrin. 
Oxidation of membrane thiol 
(-SH) groups.
Loss of spectrin and ankyrin correlated with 
membrane thiol (-SH) oxidation, α-chain 
autoxidation, and heme release.
Cellular 
deformability
Decreased cellular and 
membrane deformability
Decreased; correlated with iron/heme 
deposition in membrane.
Intracellular oxidant 
stress
Evidence supporting increased 
oxidative damage
Increased H2O2; correlated with α-chain 
autoxidation & heme release.
Oxidant 
susceptibility
Increased Increased; correlated with membrane bound 
iron/heme.
Membrane bound 
iron/heme
Increased membrane associated 
hemoglobin & Heinz body 
formation
Increased membrane heme; correlated with 
α-chain autoxidation.
Short in vivo survival + + (murine model β Thal RBC)
Table 2. 
Comparison of the pathologic characteristics of β thalassemic and model β thalassemic erythrocytes [18–27].
Parameter N Normal Resealed* Model β 
thal*
Model α thal*,**
Mean cell volume (μm3) 7 88.9 ± 1.5 85.8 ± 4.5 78.6 ± 0.8 76.0 ± 4.0
Mean cell hemoglobin (pg) 7 30.5 ± 0.8 28.5 ± 2.7 23.4 ± 0.6 26.9 ± 2.1
Mean cell Hb conc. (g/dl) 7 34.2 ± 0.7 33.2 ± 1.7 29.6 ± 0.6 35.5 ± 1.3
Red cell distribution width 
(RDW)
7 12.9 ± 0.2 17.5 ± 4.5 29.2 ± 0.5 21.3 ± 3.8
*Immediately post resealing and washing 3×.
**Made via the entrapment of purified human β hemoglobin chains.
Table 1. 
Cellular characteristics of model β and α thalassemic RBC [18–27].
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Entrapment of the purified α-chains within normal erythrocytes is done by 
osmotic lysis and resealing as previously described [18–34]. Briefly, washed, packed 
erythrocytes (80–85% hematocrit) are mixed with the purified CO-α-chains 
(10 mg/ml packed red cells) and then placed as a thin film within 11.5 mm diameter 
dialysis tubing (MW cutoff of 3500). The samples are dialyzed against a hypotonic 
lysis buffer (5 mM potassium phosphate buffer and 2 mM EDTA; pH 7.4) at 4°C 
for 60 min. The dialysis tubing is then transferred to an isotonic resealing buffer 
(5 mM potassium phosphate, 160 mM NaCl, and 5 mM glucose; pH 7.4) with gentle 
agitation for 30 min at 37°C. Following resealing, cells are washed with saline until 
the supernatant is clear. Using this procedure, approximately 70–80% of the initial 
packed erythrocyte volume is recovered. Radiolabeled α-chains can be utilized to 
quantitate the intracellular entrapment [18, 20].
To determine whether the model β thalassemic erythrocytes exhibit the cellular 
abnormalities characteristic of true β thalassemic cells, a number of cellular param-
eters have been examined. The results of these studies demonstrate that the α-chain 
loaded erythrocytes exhibit structural and functional changes very similar to those 
seen in β thalassemic erythrocytes (Table 2). Consequently, this model allowed for 
the systematic examination of the mechanisms underlying the α-chain mediated 
damage within the β thalassemic RBC and to directly determine the ontogeny of the 
pathologic events underlying the RBC injury and to experimentally test potential 
therapeutic approaches.
3. Iron-glutathione driven progeria of the thalassemic RBC
Containing approximately 20 mM iron, the RBC is the most ferruginous somatic 
cell in mammals. Under normal conditions, most of this iron is complexed within 
hemoglobin (as heme) with virtually none present as free metal (i.e., non-heme). 
This near perfect compartmentalization of iron may, however, break down in 
certain pathologic states such as β thalassemia and sickle cell disease resulting in the 
autoxidation of hemoglobin (i.e., formation of methemoglobin and hemichromes). 
Of physiologic importance, the monomeric α-chains spontaneously autoxidize to 
Figure 3. 
Free radical basis of α-hemoglobin autoxidation and free radical injury. Consequent to the formation of 
methemoglobin, the non-covalently bound heme is 8-times more likely to escape the globin chain. Release of the 
heme initiates iron-dependent free radical reactions. References: [18–27
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methemoglobin, simultaneously generating superoxide (O2
−), at a rate 8-times that 
of normal hemoglobin (Figure 3) [18, 20, 22–27, 37–39]. Moreover, consequent to 
the formation of methemoglobin, the non-covalently bound heme is more likely 
to escape the heme pocket of the globin chain giving rise to elevated levels of 
free, redox-active, intraerythrocytic iron. The O2
− produced via the autoxidation 
of hemoglobin can reduce ferric (Fe+3) to ferrous (Fe+2) iron or form hydrogen 
peroxide (H2O2; either spontaneously or enzymatically via superoxide dismutase). 
Importantly, the iron, O2
−, and H2O2 can, via the Haber-Weiss Reaction, give rise 
to the formation of the ‘dreaded’ hydroxyl radical (•OH) which rapidly reacts with 
virtually all biological constituents converting pristine materials into biological 
garbage (Figure 3). However, despite the general concept that free iron and the 
formation of free radicals are bad, the actual iron-dependent pathophysiology of 
the β thalassemic RBC has been poorly understood.
Mechanistically, studies using the model β thalassemic RBC have demonstrated 
that the initial autoxidation of the unpaired α-chains initiates an iron and reduced 
glutathione (GSH) dependent, self-amplifying and self-propagating reaction with 
the subsequent release of even more heme and, eventually, free iron. Schematically, 
this self-amplifying, self-propagating injury pathway is shown in Figure 4. As noted, 
the reaction process is initiated by the autoxidation of the unpaired α-chains which 
gives rise to the release of free heme and the generation of O2
−. Interestingly, at this 
Figure 4. 
Damage to multiple components of the β thalassemic RBC is mediated by an Fe-GSH dependent mechanism. 
As thalassemic RBC circulate, α-hemoglobin chains autoxidize (A) giving rise to superoxide (O2
−) and 
methemoglobin [MetHb]. The heme moiety of the α metHb chains are released yielding free heme and globin 
(B). Free heme reacts with reduced glutathione [GSH; reaction (C)] resulting in cleavage of the heme group 
and the formation of a glutathione radical (GS•) and the release of free Fe+2 (D). The free iron (E) reacts with 
hemoglobin derived reactive oxygen species (ROS: O2
− and H2O2) to generate •OH – A highly reactive radical 
capable of damaging all cellular components including cellular metabolism and cation/anion balance. The 
ferric iron (Fe+3), in the presence of additional GSH or O2
− regenerates Fe+2 which then oxidizes additional 
hemoglobin (F). Reactions (G) and (H) represent subsequent oxidative and non-oxidative injury to the cell. 
Oxidative pathway generated from references: [18–27, 40].
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point, a key component of this pathway is GSH; an ‘anti-oxidant’ present at high 
intracellular (~2.3 mM) concentrations within the RBC [41, 42]. GSH readily reacts 
with free heme resulting in the cleavage of the heme ring, the release of free iron, 
and the formation of a thiol radical (GS•). This reaction leads to the rapid amplifica-
tion of the oxidative damage to the RBC [18, 20, 22–27]. .The importance of the 
released iron and GSH was documented experimentally. As shown in Figure 5A, 
addition of Fe+3 to hemolysates from normal RBC results in the rapid oxidation of 
oxyhemoglobin in an iron-dose dependent manner. The oxidation of hemoglobin 
can be inhibited by the inclusion of an iron chelator (shown is deferoxamine; DFO) 
or by chemical depletion of GSH (not shown) [23, 27]. Moreover, in the intact model 
β thalassemic RBC, chemical depletion of GSH inhibited iron-driven hemoglobin 
oxidation (Figure 5B) [23, 27]. In contrast, as shown in Figure 5C, increasing the 
amount of intracellular GSH (via osmotic lysis and resealing; see Figure 2) in the 
model β thalassemic RBC significantly exacerbated injury to the cell. This enhanced 
injury is readily seen by the significantly reduced deformability (i.e., increased mean 
cell transit time) of the GSH-loaded model β thalassemic cells relative to the control 
model β thalassemic RBC. Importantly, as shown, GSH supplementation of normal 
RBC in the absence of iron had no detrimental effects on cellular deformability.
The enhanced oxidative stress, and consumption of GSH, was further noted by 
the time dependent decrease in GSH noted in the model β thalassemic RBC (Table 3) 
[27]. Moreover, a decrease in the NADPH/NADPtotal ratio was noted. NADPH is 
utilized to regenerate reduced GSH from oxidized (GSSG) glutathione via gluta-
thione reductase. This decrease in the NADPH/NADPtotal ratio is likely reflective of 
both the high GSH-GSSG-GSH cycling but also of metabolic abnormalities arising 
consequent to iron and free radical mediated inhibition of normal glucose metabo-
lism (Figure 4). Also of physiological importance, was the finding that the model 
β thalassemic RBC exhibited significantly (p < 0.001) decreased catalase activity 
Figure 5. 
Role of iron and GSH in the destruction of the β thalassemic RBC. (A) Fe+3 is a potent accelerator of 
hemoglobin oxidation. Shown is the oxyhemoglobin concentration following the addition of 100, 175 and 
250 μM Fe+3 to a fresh RBC hemolysate. In contrast to the Fe+3-treated samples, no oxidation was observed 
in the absence of added Fe+3 or in the presence of an iron chelator [DFO (deferoxamine) or, not shown, the 
tripeptide Gly-His-Lys]. Also shown are sequential, hemoglobin scans of the hemolysates treated with Fe+3. The 
time, in minutes, of the individual scan line following addition of Fe+3 are indicated [23, 27]. (B) Depletion 
of GSH in model β thalassemic RBC inhibits hemoglobin oxidation. Shown is the percent oxyhemoglobin in 
control-resealed and model β thalassemic cells RBC over 27 h at 37°C. GSH was depleted by treatment with 
1-chloro-2.4-dinitrobenzene (CDNB) as previously described [18, 20, 31, 32]. (C) Elevated intracellular GSH 
levels in model β thalassemic RBC adversely affects cellular deformability as demonstrated by the cell transit 
analyzer. Less deformable cells take much longer to transit through a pore of known diameter and length. The 
results shown are the mean ± S.D. of a minimum of four experiments with >2000 RBC measured at each time 
point. From references: [23, 27].
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(Table 3). Catalase is the pre-eminent defense against H2O2 within the RBC, mak-
ing β thalassemic cell particularly increasingly sensitive to H2O2 generated via the 
pathway described in Figure 4 [31–34, 43]. Following 20 h incubation at 37°C, only 
61.5 ± 2.9% of the initial catalase activity remained in the α-hemoglobin chain loaded 
cells versus 104.6 ± 4.5% in the control RBC. The loss of catalase arose due to the 
decrease in the NADPH/NADPtotal ratio as studies have demonstrated that NADPH 
is essential for maintaining catalase in an enzymatically active state [31–34, 43–47]. 
Indeed, as noted in Table 3, the model β thalassemic erythrocytes exhibit a signifi-
cant decrease in the NADPH/NADPtotal ratio similar to that seen in severe G6PD 
deficiency. Hence, consequent to the oxidation of hemoglobin and the formation of 
free radicals in the thalassemic RBC, significant metabolic and functional changes 
are noted in the model β thalassemic RBC that mirror those seen in patient derived 
samples (Figure 4 and Table 2). It is also important to note that non-oxidative driven 
damage also occurs. As shown in Figure 4, precipitated globin proteins, as well as 
iron and heme, can alter the intracellular viscosity of the cytoplasm and interact with 
the cytoskeleton and membrane lipids resulting in mechanical dysfunction. These 
oxidative and non-oxidative injuries can dramatically affect the function of the RBC.
4. Loss of RBC deformability and vascular survival
From a functional standpoint, perhaps the most important consequence of the 
oxidative changes to the β thalassemic RBC, as well as other RBC abnormalities, 
is the loss of cellular deformability [18–27, 29–33, 48–52]. The physiology, fluidics 
and vascular bed of the circulatory system impart unique rheological stresses on cir-
culating RBC (Figure 6A) [53]. These include extreme variations in shear stress and 
viscosity as well as biomechanical obstacles (e.g., capillaries and splenic filtration). 
With an average resting cardiac output of approximately 5 L/min, blood flow varies 
from approximately 40 cm/s in the aorta to 0.03 cm/s in the smallest capillaries 
[53, 54]. Moreover, blood viscosity (affecting shear stress) is also variable. At high 
RBC counts and high flow rates, blood is highly viscous while at low RBC counts 
and low flow rates (capillaries), blood viscosity is greatly reduced. Rheological 
stress is further exacerbated by the biomechanical stresses induced by the extreme 
disparity in the size of RBC (~8 μm) to the minimum diameter of the vascular capil-
lary beds (4–5 μm) and splenic interendothelial clefts (0.5–1.0 μm) [55, 56]. Hence, 
consequent to the shear forces, viscosity and biomechanical stresses placed on 
blood cells, a key biologic/physiologic requirement of the RBC within the vascular 
space is rheological deformability. Biomechanically, the intracellular viscosity 
and membrane rigidity of the RBC are the key factors in imparting their vascular 
Population Hours 
(37°C)
GSH (μmol/g Hb) NADPH/NADPtotal 
(1.0 = Normal)
Cat. activity (IU/g Hb)
Control 
RBC
0 5.6 ± 0.4 0.870 147,300 ± 17,000
20 6.0 ± 0.6 1.063 154,100 ± 14,800
Model β 
Thal
0 5.2 ± 0.3 0.898 145,600 ± 12,300
20 2.1 ± 0.0* 0.478* 89,540 ± 8200*
Modified from [27].*p < 0.001 from time-matched Control RBC.
Table 3. 
Association between NADPH, GSH and catalase.
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rheological deformability; both of which can be dramatically altered consequent to 
hemoglobin oxidation, heme release and/or redox-damage to cytoplasmic, cytoskel-
etal, or membrane components (Figure 4) [57–68]. Indeed, as shown in Figure 6B, 
Figure 6. 
Vascular deformability of model β thalassemic RBC. (A) The vascular bed is composed of blood vessels of 
various sizes which create significant disparity in blood (fluid and cellular) velocity consequent to vessel 
diameter. The fluid flow induces rheological sheer stress while the vessel size creates biomechanical deformation 
of cellular elements. Shown is an RBC undergoing deformation in a microfluidic channel. (B) Ektacytometric 
analysis of α-chain loaded RBC demonstrate that these chains dramatically reduce the sheer-induced shape 
change of the cell [24]. Ektacytometry bests approximates high flow rates. (C) The mean cell transit time (in 
ms) of model β thalassemic cells was significantly increased, similarly to that observed in patient samples [20]. 
This microfluidic flow best approximates capillary flow.
Figure 7. 
Model β thalassemic RBC are immunologically recognized and cleared rapidly from the peripheral circulation 
in vivo. (A) Blood group A RBC that were loaded with purified α-chains were phagocytosed by human 
monocytes. Shown for comparison are control cells from the same donor that were either unopsonized or 
opsonized with an anti-A blood typing antibody. (B) Model β thalassemic mouse RBC were made by the 
entrapment of purified human α-hemoglobin chains within Normal murine RBC. Oxidatively damaged RBC 
were made by treating mouse RBC with 50 μM phenazine methosulfate (PMS) for 2.5 h then washing. Both 
PMS-treatment and the entrapment of α-hemoglobin chains lead to membrane iron deposition and extensive 
RBC oxidation. The model β thalassemic and PMS-treated RBC have half-lives of 4 and 7 days, respectively 
in the peripheral circulation versus 26 days for normal murine RBC. Shown is the percent total RBC mass that 
is PKH-26 labeled. Inset: The peripheral blood lifespan of the human β thalassemic RBC are approximately 
6–10 days in a patient with a functioning spleen and 12–16 days in a splenectomized individual. Normal RBC 
circulates approximately 120 days, data modified from Blendis et al. [69].
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ektacytometric analysis of the model β thalassemic RBC shows a significant loss of 
cellular deformability induced by shear stress (e.g., large vessels). Moreover, cell 
transit analysis of these cells (analogous to capillary deformation) showed a very 
significant loss of deformability in the model β thalassemic cells as reflected by the 
very large and significant increase in transit time (Figure 6C).
Consequent to the loss of deformability and immune recognition (e.g., Kupffer 
cells of the liver and, potentially, antibodies), the circulatory survival of β thalas-
semic RBC is impacted. As demonstrated in Figure 7A, model β thalassemic RBC 
(Blood group A) exhibited enhanced immune recognition and phagocytosis by 
autologous monocytes when compared to control cells from the same donor. 
Indeed, the level of phagocytosis was similar to that of the anti-A opsonized posi-
tive control RBC. The loss of deformability and enhanced immune recognition both 
contribute to decreased in vivo survival. This was demonstrated using mice trans-
fused with model β thalassemic murine cells (mouse RBC + human α-chains) in 
which the transfused RBC exhibited a dramatic reduction in the circulatory lifespan 
(Figure 7B). The role of α-chain mediated oxidation was supported by the find-
ing that lightly oxidized (phenazine methosulphate treated; 50 μM) murine cells 
showed similar circulatory dynamics. These results are comparable to that observed 
in humans where, consequent to the α-chain driven oxidation, β thalassemic RBC 
have a very short circulatory lifespan (7–14 days depending on spleen status) 
compared to the 120 days of a normal RBC.
5. Immunological dysfunction: Effect on antigen presentation
Interestingly, thalassemias have been clinically associated with an increased risk 
of recurrent bacterial infections [70–87]. This is most evident in under-developed 
nations where sanitary and medical facilities are most lacking. Despite the clinical evi-
dence of recurrent bacterial infections in thalassemic patients, the biological events 
underlying this finding are unclear. This confusion arises as a natural consequence of 
the heterogeneity of the microbial disease itself, the patients age, the state of splenic 
function, the frequency of transfusion, the degree of similarity between the patient 
and the blood donor pool, the nutritional status of the patient (e.g., United States 
versus Thailand) and whether one is looking at humoral or cell-mediated immunity 
[70–87].
In general, studies on the humoral (i.e., immunoglobulin-based) immunity 
of thalassemic patients suggest that this arm of the immune system is ‘relatively’ 
normal. These studies have indicated normal to elevated levels of IgG, IgA, and 
IgM but decreased levels of Factor B, C3, and C4 (perhaps due to consumption 
via oxidatively damaged β thalassemic cells). Reflective of this normality, and 
consequent to the extensive oxidant injury to the thalassemic cells, circulating 
immune complexes and an elevated risk of autoimmune hemolytic anemia have 
been described in β thalassemia intermedia and major patients. Serum fractions 
from these patients also exhibited increased amounts of C1q-precipitable immune 
complexes. In contrast, as suggested by the clinically described recurrent bacterial 
infections, cell-mediated immunity is highly suspect in the thalassemic patient (and 
sickle cell patients). The few direct studies on cell-mediated immunity in thalas-
semic patients were, typically, enumeration of the mononuclear cell populations 
(T cells, B cells, NK cells and monocytes). In general, these studies suggest normal 
cell numbers but a skewed distribution of the CD4+ to CD8+ T cell ratio. The altered 
ratio was characterized by a relative depression in CD4+ T cells (i.e., helper T cells) 
and NK (Natural Killer) cells and a relative rise in CD8+ (cytotoxic and suppressor) 
T cells that increased linearly with the number of units transfused. However, very 
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few functional studies have been done in thalassemic patients to answer the ques-
tion: Why are β thalassemic patients at risk of recurrent bacterial infections?
Previous studies have suggested that increased bioavailable iron in transfused 
patients might facilitate the growth of organisms in which iron is a limiting nutri-
ent (i.e., most bacteria). Other studies have implicated the loss of splenic function. 
While both of these factors may indeed play important roles in recurrent bacterial 
infections, they may not offer a complete explanation. In addition to thalassemia, 
a number of other diseases and trauma scenarios are characterized by recurrent 
bacterial infections (e.g., malaria and burn injury) suggestive of impaired cell-
mediated immunity. Interestingly, a common characteristic of all these conditions is 
erythrophagocytosis. Previous studies have demonstrated that phagocytic uptake of 
IgG-coated and oxidatively stressed RBC resulted in a transient depression of further 
macrophage phagocytosis, decreased respiratory burst (i.e., NADPH-oxidase activ-
ity; O2
− production), and impaired killing of bacteria [88–93]. Interestingly, in the 
case of Plasmodium falciparum-infected RBC, only phagocytosis of mature (tropho-
zoite), but not immature (ring stage), stages had an inhibitory effect on monocyte 
function. Importantly, a major difference between the mature and immature malar-
ial infected RBC is the presence of malarial pigment (hemozoin), an iron/heme rich 
degradation product of parasite hemoglobin catabolism. Τhe heme- and iron-rich 
membranes of the β thalassemic RBC, which we have previously documented [22], 
may function in a manner analogous to malarial pigment or iron salts and impair 
cell-mediated immunity—primarily at the level of the APC but potentially extending 
to the T cell level. Some data from thalassemic patients support the hypothesis for 
impairment of the T cell response. For example, patients with thalassemia intermedia 
have been reported to have diminished T cell mitogen responses when their serum 
iron and ferritin were higher than 200 and 600 μg/dl, respectively [94].
Hence, injury arising from the iron-GSH pathway can result in (any combina-
tion of) RBC opsonization by endogenous antibodies, phosphatidylserine (PS) 
exposure, protein clustering, sublytic levels of complement binding, and/or loss 
of cellular deformability (Figure 7) that leads to the removal of the damaged β 
thalassemic cells from the circulatory system by components of the mononuclear 
phagocytic system (MPS). Erythrophagocytosis can occur within the spleen (if 
present and functioning), liver (Kupffer cells) or the microvasculature itself when 
Figure 8. 
Antigen processing and presentation is inhibited by oxidized RBC and hemin. (A) Antigen presentation of TT 
and SM was inhibited by the erythrophagocytosis of oxidized RBC. Normal RBC had no inhibitory effect. The 
efficacy of antigen processing and/or presentation was assessed by 3H-thymidine incorporation in proliferating 
T cells. PBMC were resuspended in Aim V media at a final concentration of 2.5 × 105 PBMC per 200 μl. 
Final RBC concentration was 8 × 106 per 200 μl. Antigens were diluted in Aim V and added at the indicated 
concentrations. Results shown are of a representative experiment with quadruplicate samples. (B, C) Heme 
pretreatment of PBMC (2 h at 37°C) dramatically inhibits the proliferative response to tetanus toxoid (B) and 
S. mutans (C). Interestingly, the ability of PBMC to respond to intact bacteria is more significantly blunted 
than is the response to tetanus toxoid at intermediate hemin concentrations (50 μM). Results shown are of a 
representative experiment with quadruplicate samples.
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non-deformable RBC are trapped and then cleared by circulating macrophages. 
Regardless of the location of removal, erythrophagocytosis results in impaired 
MPS function. As shown in Figure 8A, antigen presentation of purified tetanus 
toxoid (TT; a peptide) or fixed, intact, S. mutans (SM; an intact bacteria) by normal 
human antigen presenting cells (APC; blood monocytes) was dramatically, and 
differentially, affected by the presence of either control (unoxidized) or oxidized 
(50 μM PMS as per Figure 7) human RBC. As shown, oxidized RBC prevented 
successful antigen presentation to human T cells while normal RBC showed no 
detrimental effects. Further experimentation demonstrated that the inhibitory 
effect was due to heme/iron. As shown in Figure 8B, C, direct addition of hemin to 
the APC impaired successful antigen presentation of both tetanus toxoid and Strep. 
mutans in a dose dependent manner.
6. Conclusions
β thalassemias arise from a number of underlying genetic defects that interfere 
with the synthesis of the β hemoglobin chain and the subsequent production of 
the normal α2β2 hemoglobin tetramer. As a consequence of this decreased/absent 
β-chain synthesis, unpaired, monomeric, α-hemoglobin chains are produced. 
While the presence of the highly unstable α-chains mediate the pathophysiology 
of the RBC, it has been difficult to fully elucidate the mechanisms underlying their 
destructive processes in human cells. This lack of understanding of the mechanisms 
of α-chain mediated damage is due, in large part, to the fact that peripheral RBC 
isolated from β thalassemic individuals are already severely damaged cells (with 
most being destroyed within the bone marrow). Moreover, severe β thalassemia 
patients are typically transfused to both correct the severe anemia accompanying 
the disease and to prevent endogenous erythropoiesis of defective RBC. Hence, 
murine models of β thalassemia have been developed and extensively studied. 
However, problems exist with these models (e.g., mouse vs. human α-chains; 
interaction of human globins with mouse cytoskeletal proteins) and these mice, as 
in human patients, still suffer from the heterogeneity of RBC changes arising from 
the different ages of the peripheral blood RBC [11–17].
To better study the fate of unpaired α-chains in human RBC, the model β thal-
assemic cell was developed [18–34]. The entrapment of purified α-hemoglobin 
chains within normal erythrocytes via osmotic lysis and resealing provides an 
excellent and reproducible human model for studying the pathologic effects of 
the unpaired α-chains on the structural and functional characteristics of the 
RBC. Indeed, as noted in Table 2, the α-chain induced structural and functional 
RBC changes are very similar to those observed in human donor derived β thalas-
semic RBC. Schematically the pathophysiology of the β thalassemic RBC, and its 
downstream consequences, as elucidated by the model human β thalassemic RBC, 
are summarized in Figure 9. Importantly, these studies have demonstrated that 
the unpaired α-chains initiate an iron, GSH-dependent, self-amplifying and self-
propagating reaction with the subsequent release of even more heme and, eventually, 
free iron (Figure 4). Membrane proteins and reactive thiol groups (not shown) 
were rapidly decreased in a pattern similar to that observed in vivo in β thalassemia 
[18, 20–23, 25–27]. These oxidative events also result in membrane vesiculation of 
the thalassemic RBC. One consequence of membrane vesiculation is the prefer-
ential loss of phosphatidylinositol (PI) anchored proteins from the RBC. Among 
these PI-anchored proteins are decay accelerating factor (DAF; CD55) and the 
membrane inhibitor of reactive lysis (MIRL; CD59) both of which play important 
roles in preventing complement-mediated binding and lysis. The effects of the 
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vesiculation-mediated loss of CD55 and CD59 can range from sublytic levels of 
bound complement enhancing phagocytosis to overt hemolysis. Indeed, a common 
endpoint for all the α-chain mediated injury is enhanced erythrophagocytosis. As 
shown, oxidized RBC or the heme from these cells (Figure 8) significantly inhibits 
antigen processing, presentation and T cell proliferation. The systemic importance 
of this on cell-mediated immunity has not be fully appreciated and may potentially 
explain the predisposition of thalassemic patients to recurrent bacterial infections.
In sum, these findings show the utility of the model β thalassemic human RBC 
for investigating the pathophysiology of the unpaired α-chains. Moreover, these 
cells are easily ‘manufactured’ from normal donor RBC and may provide an effec-
tive means to evaluate therapeutic approaches to ameliorate the damage to the 
thalassemic cell in β thalassemia intermedia in order to prolong RBC survival and 
reduce transfusions [23, 25–27, 40].
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